ICBI UPDATE ON THE ROAD TO THE CURE CONSUMERS USE CAUTION BEFORE USING FAST TRACK FDA APPROVED DRUGS

CONSUMERS USE CAUTION BEFORE USING FAST TRACK FDA APPROVED DRUGS Helplessness makes us susceptible to fall victims to the surroundings. This is exactly what happened to the numerous Parkinson’s disease patients who, due to the debilitation and frightening psychosis, felt helpless and became victims to Acadia’s Nuplazid, a drug approved by the … [Read more...]

ICBII UPDATE ON THE ROAD TO THE CURE – PROMISING PRELIMINARY RESULTS FROM TREATMENT OF ALZHEIMER’S AND LEWY BODY PATIENTS WITH AN ANTIBODY DRUG

ICBI UPDATE ON THE ROAD TO THE CURE PROMISING PRELIMINARY RESULTS FROM TREATMENT OF ALZHEIMER’S AND LEWY BODY PATIENTS WITH AN ANTIBODY DRUG Debilitation due to neurodegenerative Alzheimer’s (AD) and Parkinson’s (PD) diseases continue to escalate as the diseases progress leaving patients and physicians helpless. According to some studies, … [Read more...]

ICBI UPDATE ON THE ROAD TO THE CURE – THE FDA SEEMS TO BE LOOSENING RESTRICTIONS ON APPROVING DRUGS FOR ALZHEIMER’S DISEASE

Could Parkinson’s Be Next? With the population living longer, neurodegenerative diseases such as Alzheimer’s (AD) and Parkinson’s (PD) diseases have become an increasing economic threat to the welfare of the world community, not to speak of the emotional toll it has taken on the patients and loved ones. According to some estimates, Alzheimer’s … [Read more...]

ICBI UPDATE ON THE ROAD TO THE CURE

(“ICBII”), Reports on the Test Results of its Potential Alzheimer’s Drug Neurodegenerative Alzheimer’s disease (AD) has become a global epidemic with more than 55 million individuals afflicted with the disease. US alone has 5.1 million Alzheimer’s patients. AD is the sixth-leading cause of death in the United States. It is the fifth-leading … [Read more...]

ICBI UPDATE ON THE ROAD TO THE CURE

ICB International, Inc., (“ICBII”) Files Orphan Drug Designation Application for Multiple System Atrophy (MSA) with the FDA MSA is a rapidly progressive neurodegenerative disease with a mean survival of 6-10 years post diagnosis. Disease onset is usually in the sixth decade with an annual worldwide prevalence of 1.9 to 4.9 in every 100,000 … [Read more...]